157 related articles for article (PubMed ID: 37271101)
21. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan.
Hu TH; Su WW; Yang CC; Yang CC; Kuo WH; Chen YY; Yeh YH; Chen SS; Tsao YY; Chen KM; Yan SL; Lai JH; Yao CD; Lim CH; Jen HH; Yeh YP; Chen SL; Chen HH; Chen SC;
Am J Kidney Dis; 2021 Oct; 78(4):511-519.e1. PubMed ID: 33940114
[TBL] [Abstract][Full Text] [Related]
22. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
[TBL] [Abstract][Full Text] [Related]
23. Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study.
McLeod A; Hutchinson SJ; Smith S; Leen C; Clifford S; McAuley A; Wallace LA; Barclay ST; Bramley P; Dillon JF; Fraser A; Gunson RN; Hayes PC; Kennedy N; Peters E; Templeton K; Goldberg DJ
HIV Med; 2021 May; 22(5):334-345. PubMed ID: 33350049
[TBL] [Abstract][Full Text] [Related]
24. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
[TBL] [Abstract][Full Text] [Related]
26. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.
Schulte B; Schmidt CS; Strada L; Rosenkranz M; Schäfer I; Verthein U; Reimer J
Clin Infect Dis; 2020 May; 70(10):2199-2205. PubMed ID: 31631215
[TBL] [Abstract][Full Text] [Related]
28. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites.
Smith BD; Teshale E; Jewett A; Weinbaum CM; Neaigus A; Hagan H; Jenness SM; Melville SK; Burt R; Thiede H; Al-Tayyib A; Pannala PR; Miles IW; Oster AM; Smith A; Finlayson T; Bowles KE; Dinenno EA
Clin Infect Dis; 2011 Oct; 53(8):780-6. PubMed ID: 21921221
[TBL] [Abstract][Full Text] [Related]
29. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China.
Zhang L; Zhang D; Chen W; Zou X; Ling L
PLoS One; 2013; 8(10):e76931. PubMed ID: 24116185
[TBL] [Abstract][Full Text] [Related]
31. HIV and hepatitis C virus testing delays at methadone clinics in Guangdong Province, China.
Xia YH; McLaughlin MM; Chen W; Ling L; Tucker JD
PLoS One; 2013; 8(6):e66787. PubMed ID: 23818964
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
[TBL] [Abstract][Full Text] [Related]
33. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
[TBL] [Abstract][Full Text] [Related]
34. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
35. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
Alavi M; Poustchi H; Merat S; Kaveh-Ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R
Int J Drug Policy; 2019 Oct; 72():99-105. PubMed ID: 31303262
[TBL] [Abstract][Full Text] [Related]
36. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark.
Demant J; Krohn-Dehli L; Van der Veen J; Øvrehus A; Lazarus JV; Weis N
Int J Drug Policy; 2023 Nov; 121():104185. PubMed ID: 37774576
[TBL] [Abstract][Full Text] [Related]
37. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
38. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States.
Zelenev A; Li J; Shea P; Hecht R; Altice FL
Clin Infect Dis; 2021 Mar; 72(5):755-763. PubMed ID: 32060534
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.
Shand FL; Day C; Rawlinson W; Degenhardt L; Martin NG; Nelson EC
Aust N Z J Public Health; 2014 Apr; 38(2):160-4. PubMed ID: 24690055
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania.
Lambdin BH; Lorvick J; Mbwambo JK; Rwegasha J; Hassan S; Lum P; Kral AH
Int J Drug Policy; 2017 Jul; 45():64-69. PubMed ID: 28628854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
